Eisai Patent-Cliff Exposure & CMS Drug Spending Portfolio
Eisai (Nutley, NJ): 7 reconciled FDA prescription therapies (0.6% 2025 to 2030 cliff risk), $1.14B 2024 CMS Part D & Medicaid spend, and 50 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Nutley, NJ |
| Reconciled FDA Portfolio Therapies | 7 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.6% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $1.14B |
| 2024 Medicare Part D Spend | $916.2M |
| 2024 Medicaid Spend | $221.0M |
| California HCAI SB 17 Filings | 50 WAC filings (max 23.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.